Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US-9452227-B2 · Sep 27, 2016 · US
Anti-IL-6 antibody for use in the treatment of cachexia
US9821057B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9821057-B2 |
| Application number | US-201514672543-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 30, 2015 |
| Priority date | Nov 24, 2009 |
| Publication date | Nov 21, 2017 |
| Grant date | Nov 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating or inhibiting cachexia in a patient receiving chemotherapy, comprising administering to the patient an effective amount of an anti-IL-6 antibody or an IL-6 binding antibody fragment comprising the variable light (V L ) chain CDR1 of SEQ ID NO:4, CDR2of SEQ ID NO:5 and CDR3 of SEQ ID NO:6, and the variable heavy (V H ) chain CDR1 of SEQ ID NO:7, CDR2 of SEQ ID NO:8 or 120, and CDR3 of SEQ ID NO:9, wherein the patient has been diagnosed with cancer and the chemotherapy agent is selected from VEGF antagonists, EGFR antagonists, platins, taxols, irinotecan,5-fluorouracil, gemcitabine, leucovorin, steroids, cyclophosphamide, melphalan, vinca alkaloids, vinblastine, mustines, tyrosine kinase inhibitors, radiotherapy, sex hormone antagonists, selective androgen receptor modulators, selective estrogen receptor modulators, PDGF antagonists, TNF antagonists, IL-1 antagonists, interleukins, IL-12R antagonists, Toxin conjugated monoclonal antibodies, tumor antigen specific monoclonal antibodies, Erbitux™, Avastin™, Pertuzumab, anti-CD20 antibodies, Rituxan®, ocrelizumab, ofatumumab, DXL625, Herceptin®, or any combination thereof.
Assignees
Inventors
Classifications
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
Drugs for disorders of the cardiovascular system · CPC title
specific for leukemia · CPC title
Immunomodulators · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9821057B2 cover?
- The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also,…
- Who is the assignee on this patent?
- Alderbio Holdings Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/454. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).